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Concise Report
Serum cytokine proﬁles and their correlations with
disease activity in Takayasu’s arteritis
M. C. Park, S. W. Lee, Y. B. Park and S. K. Lee
Objective. To investigate serum proﬁles of inﬂammatory cytokines in patients with Takayasu’s arteritis (TA) and to determine
their correlations with disease activity of TA.
Methods. Forty-nine patients with TA and 12 age- and sex-matched controls were studied. Blood samples were obtained and
were divided into active and stable disease groups. Paired blood samples were available in 19 patients at the active stage before
treatment and at the remitted stage after treatment. Serum tumour necrosis factor (TNF)-a, interferon (IFN)-c, interleukin
(IL)-6, IL-12 and IL-18 levels were determined by enzyme-linked immunosorbent assay.
Results. Serum TNF-a, IL-6 and IL-18 levels of patients with TA were signiﬁcantly higher than those of controls (P<0.05), but
IFN-c and IL-12 levels were not. Serum IL-6 and IL-18 levels were signiﬁcantly higher in the active disease group than in the
stable disease group (P<0.05), but the levels of TNF-a were not different between the groups. In the 19 patients with paired
samples, serum IL-18 levels at the remitted stage after treatment were signiﬁcantly decreased compared with the active stage
before treatment (P<0.001). The changes in IL-18 levels between active and remitted stages correlated well with changes in
erythrocyte sedimentation rate (P<0.001).
Conclusion. Serum IL-18 and IL-6 levels were elevated in patients with TA, especially in those with active disease. Serum IL-18
levels correlated well with disease activity of TA. These results suggest that IL-6 and IL-18 might contribute to the pathogenesis
of TA and that IL-18 could be a useful marker for monitoring disease activity of TA.
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Takayasu’s arteritis (TA) is a chronic granulomatous vasculitis
that involves large vessels such as the aorta and its branches [1].
Vascular inﬂammation of TA originates in the vasa vasorum and
is followed by inﬁltration of various inﬂammatory cells, leading
to the formation of granulomas. At this stage, the production
of inﬂammatory mediators is markedly increased [2, 3]. Previous
studies have reported increased expression of interleukin (IL)-1
and IL-6 in aortic tissues from patients with TA, which were locally
produced at the site of inﬂammation in TA [4], and serum levels of
IL-6 correlated well with the disease activity of TA [5]. A recent
report showed up-regulated mRNA expression of TNF- from
peripheral blood mononuclear cells (PBMCs) from patients with
TA [6].
TA has a feature of granuloma formation on vessel walls, and
several proinﬂammatory cytokines, including tumour necrosis
factor (TNF)-, interferon (IFN)-, IL-6, IL-12 and IL-18, are
known to be associated with granuloma formation in inﬂamma-
tory diseases, such as pulmonary tuberculosis, giant cell arteritis
and Wegener’s granulomatosis [7–12]. However, studies on the
comprehensive proﬁles of these cytokines and on the changes in
their levels along with disease activity of TA are lacking.
Moreover, the use of biological agents that block the inﬂammatory
cytokines has not been established in TA.
To investigate serum proﬁles of inﬂammatory cytokines that are
involved in granuloma formation and their correlations with
disease activity in TA, and to provide evidence for the use of
biological agents in TA, we evaluated serum TNF-, IFN-, IL-6,
IL-12 and IL-18 levels in patients with TA.
Patients and methods
Patients and clinical assessments
Forty-nine patients with TA fulﬁlling the American College of
Rheumatology 1990 criteria for the classiﬁcation of TA [13] and 12
age- and sex-matched healthy controls were studied. All patients
with TA were divided into two subgroups according to their
disease activity at study enrolment: an active disease group (n¼ 34)
and a stable disease group (n¼ 15). The disease activity was
assessed using the National Institutes of Health criteria for active
disease, as suggested by Kerr et al. [1]. These criteria include
systemic features, such as fever and musculoskeletal symptoms; an
elevated erythrocyte sedimentation rate (ESR; reference value
<15mm/h in men and <20mm/h in women); features of vascular
ischaemia or inﬂammation, such as claudication, diminished or
absent pulse, bruit, vascular pain, and blood pressure difference
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in either upper or lower extremities; and typical angiographic
ﬁndings. New onset or worsening of two or more features was
deﬁned as active disease, and reduction of symptoms and signs or
complete resolution of clinical features were deﬁned as stable
disease. Among the 34 patients who initially had an active disease,
19 were followed for the remainder of the study, with a mean
duration of 10.9±6.9 months. All of the 19 patients were treated
with glucocorticoid, while a subset of 11 were also given
immunosuppressive agents, such as methotrexate (n¼ 9) or
azathioprine (n¼ 2). After the follow-up period, remissions were
achieved in the 19 patients and their paired blood samples were
obtained. Achievement of remission was deﬁned as having a
stabilized disease for more than 6 months in patients who
previously had active disease.
Angiographic assessment
All patients with TA underwent aortic angiography at the time of
diagnosis and the angiographic ﬁndings were classiﬁed according
to the International Takayasu’s Arteritis Conference of 1994 [14].
This classiﬁcation was as follows: type I, involvement of the main
branches from the aortic arch; type IIa, involvement of the
ascending aorta, aortic arch and its branches; type IIb, involve-
ment of the ascending aorta, aortic arch and its branches, thoracic
descending aorta; type III, involvement of the thoracic descending
aorta, abdominal aorta, and/or renal arteries; type IV, involvement
of the abdominal aorta and/or renal arteries; and type V, the
combined features of type IIb and IV. Sixteen (32.7%) of the 49
patients had type I and three (6.1%) had type II, which included
one type IIa (2.0%) and two type IIb (4.1%). Five patients (10.2%)
had type III, 10 (20.4%) had type IV and 15 (30.6%) had type V.
Measurement of cytokines and acute-phase reactants
Blood samples were obtained from all patients and controls. Serum
specimens were separated by centrifugation at 3000 r.p.m. for
7min and stored at 208C until assayed. Commercial enzyme
linked immunosorbent assay (ELISA) kits were used for the
measurement of serum TNF-, IFN-, IL-6, IL-12 (R&D Systems,
Minneapolis, MN, USA) and IL-18 levels (Medical and Biological
Laboratories, Nagoya, Japan) according to the manufacturer’s
instructions. The white blood cell (WBC) count, ESR (modiﬁed
Westergren method) and C-reactive protein (CRP) levels were
measured at the same time point as the collection of samples for
measurement of cytokine levels.
Statistical analysis
The t-test, 2 test and analysis of variance with multiple
comparisons were used to evaluate the differences in demographic,
laboratory and angiographic features between the study groups.
Mann–Whitney U-tests were used to evaluate the differences in
serum cytokine levels between groups and between stages, and the
correlation coefﬁcient was obtained by Pearson’s correlation test.
P values less than 0.05 were considered statistically signiﬁcant.
Results
Subject characteristics
Demographic, laboratory and angiographic characteristics of
subjects are summarized in Table 1. Mean ESR of the patients
with active disease was signiﬁcantly higher than those of the
patients with stable disease and the controls (P<0.01). However,
the mean ESR level of those with stable disease was not
signiﬁcantly different from that of controls. Sex distribution,
mean age, CRP levels, WBC counts, mean disease duration from
diagnosis of TA to study enrolment, and angiographic types were
not different between those with active disease and those with
stable disease. In 19 patients who were followed for the remainder
of the study, ESRs measured after the follow-up period were
signiﬁcantly decreased compared with those measured initially
TABLE 1. Characteristics and serum cytokine levels of patients with TA and controls at baseline and after follow-up period
At baseline
Active group Stable group Controls After follow-up
n 34 15 12 19
Age (years) 33.4±13.0 34.1±12.0 33.3±10.0 34.1±13.3
Males/females 2/32 1/14 1/11 1/18
Disease duration (months) 29.4±27.1 31.4±22.9 – 39.9±27.7
Laboratory ﬁndings
ESR (mm/h) 44.4±19.0*yy 12.5±8.8 9.1±4.3* 17.2±9.6yy
CRP level (mg/dl) 1.4±1.0 0.5±0.5 0.3±0.2 0.8±0.5
WBC count (/mm3) 11 500±5990 8880±4410 6900±2110 9270±5020
Angiographic classiﬁcation
Type I 11 (32.6%) 5 (33.3%) – –
Type IIa 1 (2.9%) 0 (0%) – –
Type IIb 1 (2.9%) 1 (6.7%) – –
Type III 3 (8.8%) 2 (13.3%) – –
Type IV 7 (23.5%) 3 (20.0%) – –
Type V 10 (29.4%) 5 (33.3%) – –
Serum cytokine levels
TNF- (pg/ml) 21.0±10.3* 14.5±9.9z 2.2±1.1*z 17.5±9.1
IFN- (pg/ml) 7.4±4.6 7.7±4.1 2.6±1.0 5.9±3.2
IL-6 (pg/ml) 54.3±21.2y 14.7±5.5z 3.21±1.0yz 39.3±21.8
IL-12 (pg/ml) 10.6±6.1 9.3±5.1 3.0±0.6 7.7±4.8
IL-18 (pg/ml) 850.0±211.1y**yy 378.7±154.1x** 98.3±21.4yx 390.0±116.5yy
Data are mean±S.D. and comparisons between baseline measurements and follow-up measurement were made only in 19 patients with paired
samples. ESR, normal value <15mm/h in men and <20 mm/h in women; CRP, normal value: <0.8mg/dl; WBC count, normal value <10 800/mm3.
*P<0.05 active group vs controls; yP<0.001 active group vs controls; zP<0.05 stable group vs controls; xP<0.001 stable group vs controls; P<0.05
active group vs stable group; **P<0.001 active group vs stable group; yyP<0.001 initial measurement vs follow-up measurement.




















(P<0.001), but CRP levels and WBC counts were not different
between initial measurements and follow-up measurements.
Cytokine levels in patients with TA and controls at baseline
Mean TNF-, IL-6 and IL-18 levels of patients with TA were
signiﬁcantly higher than those of controls (P<0.05), but mean
IL-12 and IFN- levels were not (Table 1). At baseline, IL-18 levels
of patients with TA correlated well with ESR levels (P<0.05), but
not with age, disease duration, CRP level and WBC count.
Baseline TNF-, IFN-, IL-6 and IL-12 levels of patients with
TA did not correlate with any of the demographic and laboratory
parameters. The differences in TNF-, IL-6 and IL-18 levels
according to the angiographic class were not signiﬁcant. However,
although statistical signiﬁcances were not found, IL-6 and IL-18
levels of patients with TA who had angiographic class V, which
represent more diffuse disease, showed a tendency to increments
compared with those of patients with TA who had angiographic
class I, which represents a localized disease (P¼ 0.083 for IL-6 and
P¼ 0.069 for IL-18). No signiﬁcant correlation was found among
levels of each cytokine at baseline.
Cytokine levels and disease activity
Mean IL-6 and IL-18 levels of the patients with active disease were
signiﬁcantly higher than those of the patients with stable disease
(P<0.05), but mean TNF-, IFN- and IL-12 levels were not
different between them (Table 1).
In 19 patients who had been given glucocorticoids and/or an
immunosuppressive agent, IL-18 levels at the remitted stage after
treatment were signiﬁcantly decreased compared with those at the
active stage before treatment (P<0.001). However, the decreases
in IL-18 levels were not signiﬁcantly different between those who
had been given glucocorticoids alone and those who had been
given glucocorticoids and an immunosuppressive agent. TNF-,
IFN-, IL-6 and IL-12 levels were not different between stages
(Table 1). The changes in ESRs between the active and remitted
stages correlated well with those of serum IL-18 levels (r¼ 0.61,
P<0.001), but not with those of serum TNF-, IFN-, IL-6 and
IL-12 levels (Table 2).
Discussion
TNF-, IFN-, IL-6, IL-12 and IL-18 are known to be involved in
the pathogenesis of several inﬂammatory diseases that feature
granuloma formation [7–12]. In pulmonary tuberculosis, TNF-,
IFN-, IL-12 and IL-18 contribute to immunity against myco-
bacterial infection and lead to the formation of granulomas [7, 8].
Also, in giant cell arteritis and Wegener’s granulomatosis, tissue
production of IL-2, IL-6, TNF- and IFN- was increased and
serum levels correlated with disease activity [9–12], suggesting their
pathogenic roles in the diseases.
In this study, we investigated serum cytokine proﬁles in TA, a
chronic granulomatous vasculitis, and evaluated their potential use
in understanding disease pathogenesis and monitoring disease
activity. We found that the patients with TA had elevated TNF-,
IL-6 and IL-18 levels compared with controls and those with active
disease had further elevated IL-6 and IL-18 levels than those with
stable disease, suggesting the possible role of these cytokines in
pathogenesis of TA. Our data are in agreement with previous
cross-sectional studies that showed an increase in IL-6 in patients
with TA and its strong association with disease activity of TA
[4, 5]. Moreover, the signiﬁcant elevation of the TNF- level in
patients with TA observed in the present study is also in agreement
with a recent report by Tripathy et al. [6] showing increased
constitutional expression of TNF- in PBMCs of 10 patients with
TA. They also found increased stimulated expression of IFN- in
patients who had apparent stable disease. However, in the present
study we could not document the elevation of IFN- in patients
with TA, even in those with active disease, and our ﬁnding
is supported by a previous report by Seko et al., which showed a
lack of IFN- gene expression in aortic tissues from patients with
TA [4].
We also found a marked reduction in serum IL-18 levels after
treatment, as well as its signiﬁcant correlation with ESR. These
ﬁndings indicate that the measurement of IL-18 levels can be used
for monitoring disease activity in the clinical setting. IL-18,
originally identiﬁed as a factor that collaborates with IL-12 to
induce IFN- production, is a potent inducer of the inﬂammatory
mediators of T lymphocytes. IL-18 and IL-12 may have a
synergistic effect to induce increased production of proinﬂamma-
tory cytokines, including IFN-, TNF- and IL-12 [15, 16]. In
contrast, it has also been suggested that IL-18, in the absence of
IL-12, enhances the cytotoxic activity of natural killer cells, leading
to Fas-mediated apoptosis and tissue damage [17, 18], and the
latter phenomenon was found in the pathology of tuberculous
granuloma [19]. Our study is the ﬁrst showing a signiﬁcant
association of IL-18 levels with disease activity of TA. Thus, we
sought to determine whether the prominent action of IL-18 in TA
is the induction of proinﬂammatory cytokines by collaboration
with IL-12 or the induction of cytotoxic activity in the absence of
IL-12, and found a lack of signiﬁcant elevations of IL-12 and IFN-
in patients with TA and the absence of their correlations with
disease activity or IL-18 levels. This ﬁnding supports the idea that
the latter action of IL-18, which is exerted through the activation of
natural killer cells and triggering apoptosis, might be involved in
pathogenesis of TA. However, we can not exclude the role of the
Th1 response in TA, because other proinﬂammatory cytokines,
such as TNF- and IL-6, were up-regulated in patients with TA
and the latter cytokine also correlated well with disease activity in a
cross-sectional manner, indicating an additional role of these
cytokines in TA. Further studies into these associations may prove
to be informative for understanding the pathogenesis of TA.
TABLE 2. Correlations of the changes in cytokine levels with the changes in acute-phase reactants levels between at active stage before treatment and at
remitted stage after treatment in 19 patients with paired samples
Change in ESR Change in CRP levels Change in WBC counts
Changes in cytokine levels r P r P r P
TNF- (pg/ml) 0.132 0.137 0.005 0.232 0.196 0.112
IFN- (pg/ml) 0.094 0.171 0.015 0.213 0.088 0.199
IL-6 (pg/ml) 0.213 0.097 0.117 0.150 0.210 0.082
IL-12 (pg/ml) 0.111 0.119 0.254 0.087 0.089 0.201
IL-18 (pg/ml) 0.610 <0.001 0.186 0.177 0.109 0.162
Results are the correlation coefﬁcients and P values calculated using Pearson’s correlation test, and the changes refer to the changes in each
parameter measured between the active stage before treatment and the remitted stage after treatment.




















Previous attempts to identify the pathogenic role of cytokines in
TA have been limited, and therefore there has been little evidence
supporting the use of biological agents for the treatment of TA
[20]. Our data indicate that IL-18 and IL-6 might be involved in the
pathogenesis of TA and that measuring their levels, particularly
IL-18 levels, would be a useful marker for following disease activity
and monitoring the therapeutic response in TA. Furthermore, our
ﬁndings provide the possibility that patients with TA, particularly
those with active disease, might beneﬁt from biological therapy
that blocks these inﬂammatory cytokines.
There are no competing interests for any of the authors.
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 Serum IL-18 and IL-6 levels were
elevated in patients with Takayasu’s
arteritis, especially in those with active
disease.
 Serum IL-18 levels correlated well with
disease activity of Takayasu’s arteritis.
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